Stephen P. Squinto
Vorsitzender bei Chemomab Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Saqib Islam | M | 54 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 11 Jahre |
Carl Gordon | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 Jahre |
David Baram | M | - |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel.
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 11 Jahre |
Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 11 Jahre |
Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
John Houston | M | 64 | 7 Jahre | |
Nissim Darvish | M | 59 |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel.
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 9 Jahre |
Dave Grayzel | M | 56 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
Leonard Schleifer | M | 71 | 36 Jahre | |
George Yancopoulos | M | 64 | 36 Jahre | |
Randy Teel | M | 45 | 6 Jahre | |
Edgar Cale | M | 60 | 5 Jahre | |
Julie Hambleton | M | 66 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 Jahre |
Adi Mor | M | 43 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 13 Jahre |
David Feldman | M | - |
GlyGenix Therapeutics, Inc.
GlyGenix Therapeutics, Inc. BiotechnologyHealth Technology GlyGenix Therapeutics, Inc. focuses on treating and curing Glycogen storage diseases. The firm’s services include development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen storage disease type 1a. The company was founded by David Feldman and Peter Kaufman in 2006 and is headquartered in Woodbridge, CT.
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 18 Jahre |
Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
Paul Carter | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 Jahre |
Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
Shoba Murali | F | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 16 Jahre |
Claude Nicaise | M | 71 | 10 Jahre | |
Maxine Gowen | M | 66 | 3 Jahre | |
Shilo Ben-Zeev | M | 50 |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel. | - |
Murray Stewart | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 Jahre |
Peter Kaufman | M | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 16 Jahre |
Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
Jeffrey Schwartz | M | 45 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 Jahre |
Alan Fuhrman | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 5 Jahre |
Freda Lewis-Hall | M | 69 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 Jahre |
Deval Patrick | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 3 Jahre |
Damien McDevitt | M | 57 |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | 3 Jahre |
Andres Bratt-Leal | M | - |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | - |
Jamie Kramer | F | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | 30 Jahre |
Jonathan Anderman | M | - | 3 Jahre | |
Elena Sukacheva | F | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 2 Jahre |
Lior Izhar | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 Jahre |
Bruce Turner | M | 60 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 Jahre |
James Sullivan | M | - |
Chamishi Therapeutics, Inc.
Chamishi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chamishi Therapeutics, Inc. is a drug discovery and development company. The company is headquartered in Deerfield, IL. | - |
Rachel Diamant | F | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 Jahre |
Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 Jahre |
Kim Diamond | F | - | 6 Jahre | |
Ian Taylor | M | 61 | 8 Jahre | |
James M. Wilson | M | - | 7 Jahre | |
Steve Weiss | M | 55 | 11 Jahre | |
Mary Gray | M | 71 | 2 Jahre | |
Todd Wider | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 6 Jahre |
Roger Abravanel | M | 77 | 3 Jahre | |
Herschel Weinstein | M | 68 | 4 Jahre | |
Ellen Chiniara | F | 65 | 2 Jahre | |
Carlos Alban | M | 61 | 2 Jahre | |
Michael Brown | M | 83 | 33 Jahre | |
Joseph Goldstein | M | 83 | 33 Jahre | |
George Sing | M | 74 | 36 Jahre | |
Neil Stahl | M | 67 | 33 Jahre | |
Phil Ferneau | M | 62 | 9 Jahre | |
Badreddin Edris | M | 37 | 6 Jahre | |
Joseph Truitt | M | 59 |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | - |
Anthony Marucci | M | 62 | 3 Jahre | |
Briggs Morrison | M | 65 | 6 Jahre | |
Jodie Morrison | F | 48 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 2 Jahre |
Andrew Spaventa | M | 39 |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | 6 Jahre |
Athena Countouriotis | M | 52 | 4 Jahre | |
Stuart M. Henderson | M | - | 3 Jahre | |
Edward Kennedy | M | 62 | 6 Jahre | |
Bill Lundberg | M | 60 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 5 Jahre |
Alan Moses | M | 76 | 3 Jahre | |
Shelia Violette | M | - |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 7 Jahre |
V. Michael Holers | M | - |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
Robbie Woodman | M | 47 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Larry Lee | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | - |
Ei Yamada | M | 74 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 4 Jahre |
Daniel Pichl | M | 41 | 4 Jahre | |
Alex Fotopoulos | M | 55 | 5 Jahre | |
James Cassidy | M | 65 | 3 Jahre | |
Brian Van Elslander | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | - |
Christopher Dawe | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | 23 Jahre |
Anna Gifford | F | - | 3 Jahre | |
Michael Nofi | M | 53 | 5 Jahre | |
Derick Duchodni | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Vered Bisker-Leib | M | 53 | 7 Jahre | |
Leonard Bell | M | 65 |
Biotechnology Research & Development Corp.
Biotechnology Research & Development Corp. Miscellaneous Commercial ServicesCommercial Services Biotechnology Research & Development Corp. provides research on animal and plant healthcare, material sciences and biotechnology. The company is headquartered in Peoria, IL. | 25 Jahre |
David Hallal | M | 56 | 10 Jahre | |
Michael V. Greco | M | 53 | 12 Jahre | |
Bruce Goldsmith | M | 58 | 2 Jahre | |
Liam Ratcliffe | M | 60 | 7 Jahre | |
Natalie Holles | F | 51 | 6 Jahre | |
Thomas Soloway | M | 55 | - | |
David Brennan | M | 70 | 7 Jahre | |
Joseph A. Madri | M | 80 | 22 Jahre | |
Eric M. Shooter | M | 100 | 26 Jahre | |
Alfred G. Gilman | M | 82 | - | |
Jill Quigley | F | 49 |
Nutrinia Ltd.
Nutrinia Ltd. Pharmaceuticals: MajorHealth Technology Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel. | 5 Jahre |
Lara Sullivan | M | 51 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 1 Jahre |
Dale Pfost | M | - | 2 Jahre | |
David W. Keiser | M | 72 | 16 Jahre | |
Kory Wentworth | M | 45 | 9 Jahre | |
Christopher Coughlin | M | 71 | 7 Jahre | |
Kathryn Murray | F | 55 |
Louisiana State University
| 5 Jahre |
Andreas Rummelt | M | 67 | 11 Jahre | |
Scott Peters | M | - | 8 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 89 | 89,00% |
Schweiz | 8 | 8,00% |
Israel | 6 | 6,00% |
Italien | 2 | 2,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stephen P. Squinto
- Persönliches Netzwerk